Skip to main content

Ildiko Lingvay

Ildiko Lingvay is Professor in the Division of Endocrinology and the Department of Population and Data Sciences at the University of Texas (UT) Southwestern Medical Center in Dallas, TX, USA. She also serves as Medical Director of the Office of Clinical Trials Management overseeing the institutional review and approval of all clinical studies and clinical trials at UT Southwestern. She sees patients at the university clinics and hospital, as well as at the Parkland Health System. 

Dr Lingvay leads a clinical research program in the field of obesity, diabetes and associated metabolic complications with the ultimate goal of improving the lives of all patients who suffer from the many health consequences of these conditions. 

Her research interests span the spectrum from pathophysiology of the disease to comparative effectiveness of therapeutic approaches. She has participated in many clinical trials in the field and has a special interest in cardiovascular trials in diabetes and obesity.  She has published over 100 manuscripts in major medical journals and has contributed to several diabetes textbooks. She is an active member of the American Diabetes Association, where she served on the Scientific Sessions Organizing Committee and currently is on the grant review committee and a board member of the WIN ADA and Focus on Fellows initiatives.

print
PRINT

Latest contributions from Ildiko Lingvay

Ildiko Lingvay

03-04-2021 | Semaglutide | Commentary | Article

STEP 2: A higher semaglutide dose in people with type 2 diabetes

Ildiko Lingvay discusses the STEP 2 findings, and why a higher semaglutide dose may be optimal for most people with type 2 diabetes (8:06).